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Abstract
Introduction: It is known from clinical practice that data concerning plasma sodium concentration and its influence on patient 
prognosis are underestimated. The aim of this study was the evaluation of the prevalence and influence of hyponatraemia on 
prognosis in patients with lung diseases, particularly with lung cancer.
Material and methods: Retrospective analysis of data obtained from a single Pulmonary Department was performed. A total of 
449 patients divided in two groups, were analysed. The first group consisted of all lung cancer patients (n = 290) hospitalized in 
the analysed period. The second group included patients with hyponatraemia but without diagnosed lung cancer (n = 159). The 
prevalence of hyponatraemia, including severity (mild, moderate or severe), was evaluated. Histological types of lung cancer as 
well as comorbidities were taken into account.
Results: Hyponatraemia was found in 46.9% of patients with lung cancer, including mild (serum sodium 135–130 mEq/L), 
moderate (129–125 mEq/L) and severe hyponatraemia (< 125 mEq/L) in 66.9%, 25% and 8.1, respectively. In patients without 
lung cancer and with recognized hyponatraemia, mild, moderate and severe hyponatraemia were found in 81.8%, 13.2% and 
5%, respectively (mainly in obstructive and interstitial lung diseases). Hyponatraemia was observed in 52.6% of patients with 
non-small cell lung cancer (NSCLC) and in 45.2% of patients with small cell lung cancer (SCLC). There was no statistical signifi-
cance in prevalence of hyponatraemia between histological types of lung cancer. In patients with lung cancer and hyponatraemia 
compared to patients with lung cancer but without hyponatraemia, a significant increase of in-hospital mortality was found (28.7% 
vs. 7.8%, respectively) p < 0.001. 
Conclusions: Hyponatraemia was a common abnormality found in approximately 50% of lung cancer patients. Hyponatraemia 
was a significant prognostic factor associated with poor prognosis. 
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Streszczenie
Wstęp: Z doświadczeń klinicznych wynika, że danym o obniżonym stężeniu sodu we krwi przypisuje się niewielką rolę. Celem 
niniejszej pracy jest ocena częstości występowania hiponatremii u pacjentów pulmonologicznych oraz jej wpływu na rokowanie 
u chorych na raka płuca.
Materiał i metody: Badanie miało charakter retrospektywny i dotyczyło chorych diagnozowanych i/lub leczonych w Klinice Cho-
rób Płuc. Badana grupa liczyła 449 chorych. Wyodrębniono dwie grupy pacjentów: chorych z rozpoznanym rakiem płuca (n-290) 
oraz pacjentów z hiponatremią wolnych od tego rozpoznania (n-159). Obliczono częstość występowania hiponatremii poszczegól-
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nych stopni w obu grupach pacjentów, w tym w przypadkach raka z podziałem na typy i podtypy histologiczne. W opracowaniu 
uwzględniono występowanie chorób współistniejących oraz stosowaną terapię. 
Wyniki: Hiponatremię stwierdzono u 46,9% chorych na raka płuca, w tym hiponatremię łagodną (Na 135–130 mmol/l), umiarko-
waną (Na 129–125 mmol/l ) i ciężką (Na < 125 mmol/l) odpowiednio u 66,9%, 25%, 8,1% pacjentów. W grupie 159 chorych bez 
raka hiponatremię łagodną stwierdzono u 81,8%, umiarkowaną u 13,2%, a ciężką u 5% chorych (głównie wśród pacjentów z roz-
poznaniem chorób śródmiąższowych i obturacyjnych). Hiponatremię rozpoznano u 52,6% chorych z rakiem drobnokomórkowym, 
u 45,2% chorych z rakiem niedrobnokomórkowym . Nie stwierdzono statystycznie istotnych różnic w częstości występowania 
hiponatremii w poszczególnych podtypach raka niedrobnokomórkowego. W grupie chorych z  rakiem stwierdzono znamiennie 
statystycznie większą częstość zgonów wewnątrzszpitalnych u pacjentów z hiponatremią tj. 28,7% v. 7,8% (p < 0,001).
Wnioski: Hiponatremia jest zaburzeniem stwierdzanym w różnych chorobach płuc, najczęściej bo u około 50% chorych z rozpo-
znanym rakiem płuca. Wystąpienie hiponatremii istotnie wpływa na gorsze rokowanie w tej grupie chorych.
Słowa kluczowe: hiponatremia, choroby płuc, rak płuca, rokowanie 
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Introduction
Tests measuring electrolyte concentration in 
the blood are the most frequently performed labo-
ratory examinations. They are carried out mainly 
to determine potassium concentration. Our clinical 
observations and the analysis of patients’ dischar-
ge reports have shown that sodium deficiencies 
are often ignored and seldom treated. The aim of 
the present study was to evaluate the prevalence 
and prognostic significance of hyponatraemia in 
pulmonological patients, including lung cancer pa-
tients, hospitalized in the Pulmonary Department.
Material and methods
The study group included 449 patients (M = 
296/F = 153) hospitalized in the Department of 
Lung Diseases and Tuberculosis at the Medical 
University of Silesia in Zabrze from November 
2010 until March 2012. The study was retrospec-
tive and it concerned diagnosed and/or treated pa-
tients. Two groups of patients were distinguished: 
all patients with diagnosed lung cancer (n = 290, 
M = 205/F = 85) (III, IV TNM stages) and all pa-
tients with hyponatraemia without lung cancer 
(n = 159, M = 91/F = 68). Patients with lung can-
cer were treated with drug doublets: in non-small 
cell lung cancer (NSCLC) — with platinum prepa-
rations and third generation drugs (vinorelbine, 
gemcitabine, pemetrexed, docetaxel, paclitaxel), 
in small cell lung cancer (SCLC) — with platinum 
preparations plus etoposide. In order to evaluate 
the prognostic significance of hyponatraemia in 
lung cancer, the data of patients with lung cancer, 
with or without hyponatraemia, were compared. 
In the group of 290 patients with lung cancer, 
in 57 patients SCLC was diagnosed, in 217 — 
NSCLC (in 80 — squamous cell carcinoma, in 85 
— adenocarcinoma, in 45 — unspecified NSCLC, 
in 4 — large cell carcinoma, in 2 — carcinoma 
male differentiatum, in 1 — pleomorphic carci-
noma); and 16 patients were not given histopa-
thological diagnosis (this group included patients 
with an undoubted neoplastic process in the lun-
gs, who due to various reasons did not undergo 
histopathological diagnosis). Based on routinely 
performed laboratory examinations, the degree 
of hyponatraemia was determined and patients 
were classified to one of three groups: mild hy-
ponatraemia (Na = 135–130 mmoL/L), moderate 
(Na = 129–125 mmoL/L) and severe (Na < 125 
mmoL/L). The prevalence of various degrees of 
hyponatraemia in the two groups of patients was 
calculated. The occurrence of comorbid diseases 
and the applied therapy were taken into account. 
In-hospital mortality was evaluated in the two 
groups of patients. Statistical analysis was made 
for independent variables by using t-student and 
chi-square tests2.
Results
The mean age of patients in the cancer group 
was 63.8 ± 9.2 years, and in the group without 
cancer it was 59.2 ± 14.1 years; p < 0.001. The 
mean age of patients with cancer and hyponatra-
emia was 63.6 ± 8.6 years, and it did not differ 
from that of patients with cancer and normona-
traemia, at 64.1 ± 9.8 years; p < 0.66.
Hyponatraemia was diagnosed in 136 (46.9%) 
patients with lung cancer. Mild, moderate and 
severe hyponatraemia were diagnosed in 91 
(66.9%), 34 (25%) and 11 (8.1%) patients, re-
spectively. In the group of 159 patients without 
cancer, mild hyponatraemia was diagnosed in 
130 (81.8%) patients, moderate — in 21 (13.2%) 
and severe — in 8 (5%) patients. Although mild 
hyponatraemia predominated in the two groups, 
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moderate hyponatraemia occurred statistically 
more often in the group of cancer patients (p < 
0.03). In order to eliminate the potential influence 
of prior therapy, the prevalence of hyponatraemia 
in patients with a newly diagnosed lung cancer 
was also analysed. Hyponatraemia was diagnosed 
in 47/136 patients (34.5%) (in 63.8% — mild, in 
21.3% — moderate, in 14.9% — severe).
Taking into account histological types, hypo-
natraemia was diagnosed in 30 (52.6%) patients 
with SCLC, in 98 (45.2%) patients with NSCLC, 
and in 8 (50%) patients without histopathological 
diagnosis (Fig. 1). After taking into consideration 
histological subtypes of NSCLC, no statistically si-
gnificant differences were found in the prevalence 
of hyponatraemia in separate subtypes, p = 0.505. 
In all histological subtypes mild hyponatraemia 
predominated (statistical significance was not 
found either, p = 0.75) (Table 1). Among patients 
with cancer not treated to date, hyponatraemia 
was diagnosed in 12 (42.8%) patients with SCLC, 
in 29 (31%) patients with NSCLC and in 6 (46.2%) 
patients without histopathological diagnosis.
In the cancer group, a higher frequency of 
in-hospital deaths was found in patients with 
hyponatraemia, i.e. 28.7% vs. 7.8% (Fig. 2). The 
difference was characterized by a high statistical 
significance p = 0.0001. The highest frequency 
of deaths occurred in patients with severe hypo-
natraemia (36.4%), then moderate (29.4%) and 
mild (27.5%), but no statistical significance was 
found for this dependence, p = 0.82 (Fig. 3). 
Among cancer patients with hyponatraemia not 
treated to date, in-hospital mortality was estima-
ted at 38.3%, whereas in the group of patients 
with hyponatraemia without lung cancer it was 
estimated at 8.2% (p = 0.08).
Figure 1. Percentage of diagnosed hyponatraemia according to lung 
cancer type
Rycina 1. Odsetek rozpoznanych przypadków hiponatremii w zależno-
ści od typu raka płuca
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(%) Table 1.  The number and the mean age of patients with 
lung cancer in the study
Tabela 1.  Liczba i średni wiek pacjentów z rakiem płuca 
objętych badaniem
Diagnosis
Cancer in total
n-290 A mean age
63.8 years
Small cell lung cancer n-57 62.8
Adenocarcinoma n-85 63.4
Squamous cell carcinoma n-80 64.9
Non-small cell lung cancer n-45 63.7
Giant cell carcinoma n-4 56.5
Carcinoma male differentiatum n-2 60.5
Pleomorphic carcinoma n-1 48.0
Lung cancer without histopathological 
diagnosis
n-16 71.1
28.7
7.8
Hyponatremia Normonatraemia
100
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0
Deaths
71.3
92.2
Alive
(%)
Figure 2. Mortality rate among patients with diagnosed lung cancer
Rycina 2. Odsetek zgonów wśród pacjentów z rozpoznanym rakiem płuca
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Figure 3. Mortality rate among patients with diagnosed lung cancer 
according to hyponatraemia severity
Rycina 3. Odsetek zgonów wśród pacjentów z rozpoznanym rakiem 
płuca w zależności od stopnia hiponatremii
The frequency of comorbid diseases that mi-
ght lead to hyponatraemia in the group of cancer 
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patients with hyponatraemia was also evaluated. 
Renal failure (GFR < 60 mL/min according to 
MDRD pattern) occurred in 30/136 (22.1%) pa-
tients, hepatic failure — in 16/136 (11.8%); and 
heart failure — in 11/136 (8.1%). In 1 patient 
adrenal hypofunction was diagnosed, and in 6 — 
hypothyroidism. 19.8% of cancer patients with 
hyponatraemia were also diagnosed with COPD, 
in 6.61% of patients bacteriologically confirmed 
inflammation of the airways occurred and in 5.1% 
— tuberculosis. Metastases to the CNS occurred 
in 21/136, i.e. in 15.4% of patients. Respiratory 
failure was diagnosed in 30.2% of all patients 
with hyponatraemia (among cancer patients it 
was 22.1%), whereas no statistically significant 
difference was found in the frequency of deaths 
in these patients compared to patients without 
hyponatraemia. Nearly 60% (58.8%) of cancer 
patients with hyponatraemia were undergoing 
therapy with platinum derivatives (cisplatin, 
carboplatin), 38.97% of patients had been using 
diuretics before cytotoxic treatment, 36.8% — 
various analgesics and 4.4% — carbamazepine.
Taking into account diagnoses in accordance 
with ICD-10, among the group with hypona-
traemia and without lung cancer, diagnosis of 
interstitial lung diseases predominated (47/159 
patients, including 17 patients with sarcoido-
sis). The remaining diseases according to their 
prevalence were: obstructive diseases (31/159; 28 
— COPD, 3 — asthma), fluid in the pleural cavity 
(14/159), pneumonia (10/159), mesothelioma of 
the pleura (9/159) and metastases to the lungs 
(5/159), obstructive sleep apnoea and haemoptysis 
(4/159 each), burns to the airways (3/159), emphy-
sema, Wegener’s granuloma, pulmonary obstruc-
tion (2/159 each), lung abscess and mediastinal 
lymphadenopathy (1/159 each). Tuberculosis or 
mycobacteriosis was diagnosed in 10 patients, 
whereas the general prevalence of tuberculosis in 
patients with hyponatraemia was 7.1%. 
In none of the 295 hyponatraemia patients 
(in the two groups with and without cancer) were 
symptoms of severe hyponatraemia observed. Hy-
ponatraemia was not a direct cause of any death. 
The disorder was included in diagnoses according 
to ICD-10 barely in 8 patients.
Discussion
Hyponatraemia is one of the most frequent 
electrolyte disorders encountered in clinical 
practice, also in lung cancer patients. Hypo-
natraemia defined as lowered (< 136 mmoL/L 
serum sodium concentration) is in the majority 
of cases a mild, chronic and asymptomatic disor-
der. The frequency of hyponatraemia in patients 
hospitalized for various reasons is estimated at 
1–40% [1], and it depends on the characteristics 
of the studied population, and on criteria used to 
decrease sodium values. In the study conducted 
by Berghmans et al. on a small group of cancer 
patients (n = 106, including 20 patients with lung 
cancer) the frequency of hyponatraemia < 135 
mmol/l found at the time of diagnosis was 3.7% 
[1]. In another study including a  significantly 
bigger group of patients with cancer metastases 
(4,702 admissions, in 3,357 patients) Doshi et 
al. found hyponatraemia in 47% of hospitalized 
patients (in 22% — hyponatraemia was diagnosed 
during admission, in 24% — it was acquired in 
hospital) — in 36% of cases mild hyponatraemia 
134–130 mmoL/L, in 10% — moderate 129–120 
mmoL/L and in 1% — severe < 120 mmoL/L was 
observed [2]. The frequency of hyponatraemia 
in lung cancer patients included in the present 
study was also high, amounting to 46.9% (66% 
— mild hyponatraemia, 25% — moderate, 8.1% 
— severe). It should be emphasized that we were 
estimating the frequency of hyponatraemia in all 
patients with lung cancer hospitalized during the 
study period, in both diagnosed and treated pa-
tients. 34.5% of these patients had hyponatraemia 
discovered at the time of diagnosis (in 63.8% — 
mild hyponatraemia, in 21.3% — moderate, in 
14.9% — severe).
Table 2. The frequency of hyponatraemia in different subtypes of NSCLC according to hyponatraemia severity
Tabela 2. Częstość występowania hiponatremii w podtypach raka niedrobnokomórkowego z uwzględnieniem stopni ciężkości 
Types of non-small cell lung cancer (NSCLC) Number of patients Hyponatraemia Mild Moderate Severe
Squamous cell carcinoma 31 38.7% 61.2% 32.2% 6.45%
Adenocarcinoma 41 48.2% 68.3% 29.3% 2.4%
Undifferentiated cell carcinoma 21 46.67% 61.9% 23.8% 14.2%
Others 5 71.0% 100% 0 0
Total 98 45.2% 66.3% 27.5% 6.1%
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In the study group, the mean age of patients 
with hyponatraemia without cancer was lower 
than in the group with cancer (59.2 ± 14.1 vs. 68.8 
± 9.2 years p < 0.001). According to the literature, 
hyponatraemia patients are older than those with 
a normal serum sodium concentration, which is 
connected, among others, with more frequent 
comorbid diseases that result in hyponatraemia, 
e.g. renal and heart failure, thyroid dysfunction 
and many others [3]. No statistically significant 
difference was found in the age of cancer patients 
with or without hyponatraemia (63.6 ± 8.6 vs. 
64.1 ± 9.8 years; p < 0.66) in the study group. We 
did not find a statistically significant difference 
in the age of patients depending on degree of 
hyponatraemia either.
Hyponatraemia in cancer patients is usually 
diagnosed in the case of SCLC [4]. In 9 studies 
including in total 1,684 patients with SCLC, 
summarised by Lassen et al. [5], hyponatraemia 
< 136 mmoL/L was found in 24.6%. In smaller 
groups, values from 25% to 44% were found 
[6–8], and in studies that excluded patients with 
mild hyponatraemia (Na 130–135 mmoL/L), this 
frequency amounted to 15% [9]. 
There are only a  few reports on the preva-
lence of hyponatraemia in NSCLC. In the study 
conducted by Jacot et al. on a group of 301 pa-
tients with NSCLC this prevalence was estimated 
at 8% [10]. 
In our group of 270 patients with lung can-
cer, hyponatraemia was diagnosed in 52.6% of 
patients with SCLC, and in 45.2% of NSCLC pa-
tients, without statistically significant differences 
in the prevalence of hyponatraemia in its separate 
subtypes. Taking into account the subgroup of 
patients receiving no treatment, hyponatraemia 
was diagnosed in 42.8% of patients with SCLC, 
in 31% of patients with NSCLC and in 46.2% of 
patients without histopathological diagnosis.
It has been shown that although the preva-
lence of hyponatraemia in cancer patients and 
patients from the general population is similar, its 
causes are different [11]. The most crucial causes 
of hyponatraemia in cancer patients are excessive 
secretion of vasopressin by tumour cells, which 
clinically manifests itself as the syndrome of 
inappropriate antidiuretic hormone secretion 
(SIADH) — the most frequent cause of normovo-
lemic hyponatraemia — and sodium loss through 
various ways (mainly through the alimentary tract 
and the kidneys) in the course of primary disease 
or due to the conducted therapy. The above causes 
in equal parts account for 2/3 of all hyponatraemia 
cases connected with cancer [12]. 
SIADH is responsible for 30% of hyponatra-
emia cases in cancer patients [1]. It is estimated 
that SIADH occurs in 15% of patients with SCLC 
and in 0.7% of patients with NSCLC. Other neo-
plasms that coexist with hyponatraemia are first 
of all carcinomas of the head and neck (3%), 
primary and metastatic tumours of the CNS, 
breast carcinoma, haematological malignancies 
(lymphomas, chronic lymphocytic leukaemia, 
multiple myeloma) and many others [13]. SIADH 
is also diagnosed in the course of many non-
neoplastic diseases: in CNS diseases (traumas, 
meningitis, encephalitis, postoperative states), 
psychoses and benign diseases of the lung and 
pleura — in pleuritis, pneumonia, tuberculosis, 
empyema and asthma. 
In the present study we were not assessing 
the prevalence of SIADH but only hyponatraemia 
per se. However, we have taken into account many 
clinical situations that could potentially influence 
the results of the present study.
In the study by Jacot et al. it has been shown 
that in 231 patients with NSCLC and metastases 
to the CNS, hyponatraemia < 132 mmoL/L was 
an indicator of poor prognosis, both in univaria-
te and multivariate analysis [14]. In the present 
study, metastases to the CNS were diagnosed in 
15.1% of hyponatraemia patients, which is very 
important in the prognosis for these patients. 
Increased ADH secretion also occurs in the 
course of respiratory failure, especially chronic. 
Respiratory failure was diagnosed in 30.1% of hy-
ponatraemia patients in the study population; ho-
wever, a statistically significant difference in the 
frequency of deaths was not found. Almost 20% 
of cancer patients with hyponatraemia were also 
diagnosed with COPD, 6.6% with inflammation 
of the upper airways and 5.1% with tuberculosis, 
which are potential causes of SIADH. It is also 
known that SIADH may be caused by numerous 
drugs used in oncological practice, among others 
cisplatin, narcotic analgesics, carbamazepine and 
antidepressants [4]. We noticed that almost 60% of 
cancer patients with hyponatraemia were treated 
with cisplatin, 36.8% were administered analge-
sics, and 4.4% — carbamazepine. Therefore, the 
impact of this factor on the general prevalence of 
hyponatraemia has to be taken into account. On 
the other hand, for the patients with cancer-related 
SIADH syndrome, cytotoxic treatment is able to 
reduce the degree of hyponatraemia. It has been 
shown that lack of initial normalization of hypo-
natraemia in patients with SCLC, after two or more 
chemotherapy cycles based on cisplatin, results 
in worse survival in 75% of cases [8].
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The next frequent cause of hyponatraemia 
in cancer patients (1/3 of all cases) is sodium 
depletion. In the case of lung cancer it happens 
mainly through the alimentary tract (vomiting 
and diarrhoea, usually drug-induced) and thro-
ugh the kidneys (usually dehydration, cisplatin 
preparations, diuretics). In the presented group, 
renal failure was diagnosed in 22.1% of patients 
with cancer and hyponatraemia, statistically 
more often than in the group with hyponatraemia 
without cancer. 39% of patients with cancer and 
hyponatraemia were using diuretics. Therefore, 
these factors might have a significant impact on 
the results. 
While looking for other causes of hyponatra-
emia in cancer patients it should be remembered 
that stress and pain may be important contribu-
ting factors [13].
Apart from the two main, already mentioned 
causes of hyponatraemia in cancer patients, there 
may coexist conditions that lead to hyponatra-
emia irrespective of the primary disease. In the 
present study hepatic failure was diagnosed in 
the cancer group in 11.8% of patients (vs. 9.4% 
in the group without cancer), heart failure — in 
8.1% (vs. 18.2% in the group without cancer), 
hypothyroidism — in 5% (the same frequency 
was observed in the group without cancer) and 
adrenocortical hypofunction occurred in 1 pa-
tient. Thus, these conditions did not occur more 
frequently in lung cancer patients than in others, 
despite the older age of cancer patients.
It was noticed that hyponatraemia, regardless 
of cause, might be the factor that increases in-ho-
spital and post-hospital mortality and prolongs 
hospitalization [2, 4, 12]. Even mild hyponatra-
emia influences the higher risk of in-hospital 
deaths [11]. It has been proven that in-hospital 
mortality increases together with the degree 
of hyponatraemia [2]. These research projects 
concern mainly patients from the general po-
pulation. Only a few of them estimate that such 
a phenomenon occurs in cancer patients. In the 
previously mentioned study by Doshi et al., it 
was shown that hyponatraemia was connected 
with worse 90-day survival, and HR amounted to 
2.04 (95% CI 1.42–2.91), 4.74 (95% CI 3.21–7.01) 
and 3.46 (95% CI 1.05–11.44) for mild, moderate 
and severe hyponatraemia, respectively [2]. In 
another previously mentioned study on patients 
with cancer metastases, Waikar et al. showed an 
increased probability of death, which was signi-
ficantly higher compared to patients without hy-
ponatraemia, and which was increasing together 
with its severity [11].
In the present study we have shown that the 
frequency of in-hospital deaths in patients with 
lung cancer and hyponatraemia was higher than 
in the lung cancer group without hyponatraemia 
(28.7% vs. 7.8%); the difference was highly signi-
ficant. Conversely, no significant differences con-
cerning in-hospital mortality were found between 
the groups with various degrees of hyponatraemia. 
In-hospital mortality was highest in the group with 
newly diagnosed lung cancer (38.3%). Therefore, 
it may be presumed that hyponatraemia negatively 
influences the prognosis in these patients.
For the last three decades many researchers 
have been trying to estimate the role of hypona-
traemia as a survival predictor in lung cancer. The 
majority of them (16 research projects conducted 
between 1982 and 2010) concerned SCLC. Hy-
ponatraemia was combined with a significantly 
shorter survival time in univariate analysis (7/13 
research projects) and in multivariate analysis 
(6/13 research projects). However, it was impos-
sible to formulate meta-analysis based on the data 
from these research projects due to a lack of HR 
value for survival in the majority of them [4]. In 
the study carried out by Hermes et al. on a group 
of 395 patients with newly diagnosed SCLC (the 
study was not included in the above-mentioned 
analysis) it was also shown that hyponatraemia is 
a negative predictor in both uni-and multivariate 
survival analysis [15]. 
Only in 3 research projects were similar 
dependencies for NSCLC analysed. In 2 out of 3 
projects, hyponatraemia turned out to be a bad 
prognostic indicator both in univariate and in 
multivariate analysis [4].
In the present study we noticed a high preva-
lence of hyponatraemia in patients with interstitial 
lung diseases - they accounted for nearly 30% of 
patients with hyponatraemia without diagnosis of 
cancer. Almost one in five patients from the group 
with hyponatraemia had COPD or asthma. In 6.2% 
of patients pneumonia was diagnosed. 
The majority of reports on the frequency of 
hyponatraemia in lung diseases and its impact on 
prognosis concern pneumonia. In the study by 
Zilberberg et al., the frequency of hyponatraemia 
that accompanies community acquired pneumo-
nia was estimated at 8.1%. They observed longer 
hospital stays in these patients, higher frequency 
of hospitalization in intensive care units, and 
mechanical ventilation [16]. However, no statisti-
cally significant difference was found (similarly 
as in the previously mentioned studies by Waikar 
et al. [11]) in the frequency of in-hospital deaths 
in these patients. 
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It should be also emphasized that although 
the frequency of hyponatraemia in hospitalized 
patients is high, barely 2% of cases with sodium 
concentration < 135mmoL/L was mentioned 
during discharge from hospital. The disorder 
was more frequently diagnosed in the case of 
severe forms of hyponatraemia, but still bare-
ly 30% of hyponatraemia with < 115 mmoL/L 
were reported and coded in accordance with ICD 
requirements [17]. This observation has also been 
confirmed by the present study. 
Conclusions
Despite many years of research, it has not 
been finally determined whether hyponatraemia 
is a significant negative predictor of survival or 
just a marker that indicates poor general con-
dition of the patient. The symptoms of chronic 
hyponatraemia are indistinct and difficult to 
distinguish from symptoms found in cancer 
patients, connected with both the disease itself 
and the conducted treatment (strength reduction, 
apathy, cognitive function disorders, headache 
and vertigo). Elimination of electrolyte disorder 
by the use of fluid restriction, infusion of iso- and 
hypertonic NaCl solutions, and possibly the use 
of V2 receptor inhibitors for vasopressin (vaptans) 
may possibly improve not only general condition 
but also prognosis in these patients. Taking into 
account the high prevalence of hyponatraemia in 
lung cancer patients and, as shown in the present 
study, the 28.7% in-hospital mortality in this gro-
up of patients, correct diagnosis and treatment of 
the disorder seems to be mandatory. 
Conflict of interest
The authors declare no conflict of interest.
References:
1. Berghmans T., Paesmans M., Body J. A prospective study on 
hyponatraemia in medical cancer patients: epidemiology, ae-
tiology and differential diagnosis. Support Care Cancer 2000; 
8: 192–197.
2. Doshi S., Shah P., Lei X., Lahoti A., Salahudeen A. Hyponatre-
mia in hospitalized cancer patients and its impact on clinical 
outcomes. Am. J. Kidney Dis. 2012; 59: 222–228.
3. Gill G., Huda B., Boyd A., Skagen K., Wile D., Watson I., van 
Heyningen C. Characteristics and mortality of severe  hypo-
natraemia — a hospital-based study. Clin. Endocrinol. (Oxf) 
2006; 65: 246–249.
4. Castillo  J., Vincent M., Justice E. Diagnosis  and  manage-
ment  of hyponatremia in cancer patients. Oncologist 2012; 
17: 756–765.
5. Lassen U., Osterlind K., Hansen M., Dombernowsky P., Berg-
man B.,  Hansen H.  Long-term survival in small-cell lung 
cancer: Posttreatment characteristics in patients surviving 5 to 
18+ years — an analysis of 1,714 consecutive patients. J. Clin. 
Oncol. 1995; 13: 1215–1220.
6. Østerlind K., Andersen P. Prognostic factors in small cell lung 
cancer: Multivariate model based on 778 patients treated with 
chemotherapy with or without irradiation. Cancer Res. 1986; 
46: 4189–4194.
7. Allan S., Stewart M., Love S., Cornbleet M., Smyth J., Leonard 
R.  Prognosis at presentation of small cell carcinoma of the 
lung. Eur. J. Cancer 1990; 26: 703–705.
8. Hansen O., Sr̸ensen P., Hansen K. The occurrence of hypona-
tremia in SCLC and the influence on prognosis: A retrospective 
study of 453 patients treated in a single institution in a 10-year 
period. Lung Cancer 2010; 68: 111–114.
9. Harper  P.,  Souhami  R.,  Spiro  S.  et al.  Tumor size, response 
rate, and prognosis in small cell carcinoma of the bronchus 
treated with combination chemotherapy. Cancer Treat. Rep. 
1982 66: 463–470.
10. Jacot W., Colinet B., Bertrand D. et al. Quality of life and co-
morbidity score as prognostic determinants in non-small-cell 
lung cancer patients. Ann. Oncol. 2008; 19: 1458–1464.
11. Waikar S., Mount D., Curhan G. Mortality after hospitalization 
with mild, moderate, and severe hyponatremia. Am. J. Med. 
2009; 122: 857–865. 
12. Tierney  W.,  Martin D.,  Greenlee M.,  Zerbe R.,  McDonald C. 
The prognosis of hyponatremia at hospital admission. J. Gen. 
Intern. Med. 1986; 1: 380–385.
13. Sørensen  J., Andersen M., Hansen H. Syndrome of inappro-
priate secretion of antidiuretic hormone (SIADH) in malignant 
disease. J. Intern. Med. 1995; 238: 97–110.
14. Jacot W., Quantin X., Boher J. et al. Brain metastases at time 
of presentation of non-small cell lung cancer: a multi-centric 
AERIO analysis of prognostic factors. Br. J. Cancer 2001; 84: 
903–909.
15. Hermes A., Waschki B., Reck M. Hyponatremia as prognostic 
factor in small cell lung cancer — a retrospective single insti-
tution analysis. Respir. Med. 2012; 106: 900–904.
16. Zilberger M., Exuzides A., Spalding J. et al. Hyponatremia and 
hospital outcomes among patient with pneumonia: a  retro-
spective cohort study. BMC Pulm. Med. 2008; 8: 16.
17. Movig K., Leufkens H., Lenderink A., Egberts A. Validity of ho-
spital discharge International Classification of Diseases (ICD) 
codes for identifying patients with hyponatremia. J. Clin. Epi-
demiol. 2003; 56: 530–535.
